Cytokinetics, Incorporated announced the first commercial European launch of Myqorzo (aficamten) in Germany for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy… read more.
Cytokinetics, Incorporated announced the presentation of new data reinforcing the clinical profile of Myqorzo (aficamten) at the European Society of Cardiology (ESC) Heart Failure 2026 Congress. The presentations… read more.
Cytokinetics, Incorporated announced that Myqorzo (aficamten) has been approved by the China National Medical Products Administration (NMPA) for the treatment of adults with New York Heart Association (NYHA)… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
